Concepedia

Karim Lebtahi

KL

Statistics

Publications

2

Citations

111

H-Index

2

Active since

2001

Affiliations

UCLouvain(Current)

Karim Lebtahi is an author at UCLouvain specializing in anticancer prodrug design, tumor-activated prodrugs, and chemotherapeutic prodrug design.

Publications per year

2001–2002

2

Publications

2

<i>N</i>-Succinyl-(β-alanyl-<scp>l</scp>-leucyl-<scp>l</scp>-alanyl-<scp>l</scp>-leucyl)doxorubicin:  An Extracellularly Tumor-Activated Prodrug Devoid of Intravenous Acute Toxicity

Anne-Marie Fernandez, Kim Van derpoorten, Luc Dasnois et al. · Journal of Medicinal Chemistry · 2001 · 77 citations

, , +17

CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

Vincent Dubois, Luc Dasnois, Karim Lebtahi et al. · PubMed · 2002 · 34 citations

, , +15

1–2 of 2